Description
Ensartinib is a third-generation ALK inhibitor. In addition, ensartinib is found to also have activity against ROS1, MET, SLK, Axl, LTK, ABL and EPHA2.
Ensartinib
Product ID E543721
Cas No. 1365267-27-1
Purity ≥98%
| Product Unit Size | Cost | Quantity | Stock |
|---|
Product Info
| Cas No. | 1365267-27-1 |
|---|---|
| Purity | ≥98% |
| Formula | C25H25Cl2FN6O3 |
| Formula Wt. | 547.41 |
| Chemical Name | 6-amino-5-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-N-[4-(4-methylpiperazine-1-carbonyl)phenyl]pyridazine-3-carboxamide |
| IUPAC Name | 6-amino-5-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-N-[4-(4-methylpiperazine-1-carbonyl)phenyl]pyridazine-3-carboxamide |
| Synonym | X396, X-396, X376, X-376 |
| Solubility | DMSO:100 mg/mL (178.11 mM) Ethanol:100 mg/mL (178.11 mM) Water:Insoluble |
Shipping and Storage
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
Downloads
| MSDS | |
|---|---|
| Info Sheet |
References
Horn L, Wakelee H, Reckamp KL, et al. MINI01.02: Response and plasma genotyping from phase I/II trial of ensartinib (X-396) in patients (pts) with ALK+ NSCLC: topic: medical oncology. J Thorac Oncol. 2016 Nov;11(11S)::S256-S257. PMID: 27969449
Caccese M, Ferrara R, Pilotto S, et al. Current and developing therapies for the treatment of non-small cell lung cancer with ALK abnormalities: update and perspectives for clinical practice. Expert Opin Pharmacother. 2016 Dec;17(17):2253-2266. PMID: 27682212
Dholaria B, Hammond W, Shreders A, et al. Emerging therapeutic agents for lung cancer. J Hematol Oncol. 2016 Dec 9;9(1):138. PMID: 27938382